Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Silvio Danese, Tadakazu Hisamatsu et al.|Gastroenterology|2025Cited by 46